スイスの過負債と過体重 - 十分に研究されていない人口の中でほとんど未知の関連性
1Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.
PloS one
|February 17, 2026
まとめ
スイスの負債過剰な個人は,過体重または肥満になるリスクが著しく高い. この研究は,特に脆弱な集団における,財政的ストレスと健康への悪影響の間の重要な関連性を強調しています.
科学分野:
- 公衆衛生は公衆衛生である.
- 社会学 社会学 社会学とは
- 健康経済学 医療経済学
背景:
- 過剰負債と肥満は,世界的な健康上の懸念が高まっています.
- この2つの症状は,社会経済的,教育的に低いグループに不釣り合いな影響を及ぼします.
- 特にスイスでは,過負債と肥満の同時発生に関する研究は限られている.
研究 の 目的:
- スイスにおける過剰負債と過剰体重/肥満の関係を調査する.
- 過剰負債の個人が,一般の人々と比較して肥満の有病率が高いかどうかを判断する.
主な方法:
- チューリッヒ州で219人の過負債顧客と1,997人の一般住民の調査データを活用した.
- 確率とリスク比率を計算するために,ロジスティックおよびポアソン回帰分析を使用した.
- 性別,年齢,教育レベルなどの人口統計的要因を制御した.
主要な成果:
- 過負債の個人は,過体重 (46%対38%) と肥満 (15%対9%) の有意に高い流行を示しました.
- 過剰負債は,超重症の相対リスクを20~36%,肥満の相対リスクを59~70%増加させた.
- これらの関連性は,性別,年齢,教育,コントロールの感覚,孤独感,またはうつ病の症状に関係なく持続しました.
結論:
- スイスでは,負債過剰と肥満の間に統計的に有意な関連性がある.
- 観測された効果の大きさは有意だったが,当初予想より小さい.
- 研究結果は,財政的および身体的健康に対処する統合的介入の必要性を強調しています.
関連する概念動画
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients
279
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
279
Stress Prevention and Stress Management Techniques IV
279
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
279
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
302
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302
Carbohydrate Metabolism
14.5K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
199
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
199


